BMYMP News and Press, Bristol-Myers Squibb $2Pr From 12/12/22

Summary Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected. The pandemic vaccine/antiviral income windfall has moved its balance sheet into a super-conservative and liquid setting. Valua...

Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend C...

Summary In today's article, we bring you the latest update in our recurring series based on analyzing 13F filings and the latest moves of some of the world's most renowned funds. Soros Fund Management still seems to be after heavily discounted technology companies, while executing succe...

Bristol-Myers Squibb Company (BMY) 4th Annual Wolfe Research Healthcare Conference November 16, 2022 03:20 PM ET Company Participants Chris Boerner - EVP and Chief Commercialization Officer Conference Call Participants Tim Anderson - Wolfe Research Pres...

Summary Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia expected in Q4 of 2022. With positive results, a Biologics Licensing Application of obe-cel for the treatment of patients...

Summary My passive income was up by 10.16% in October. Year-to-date, my passive income was up by 22.10%. I made 20 trades in October; 15 buys and 5 sales. Another month, another step towards financial freedom. It never gets old writing that. I never tire of s...

Summary IGD invests in a portfolio of dividend-paying stocks and options in order to generate a high level of income for investors. The portfolio is quite well-designed for the current environment and has outperformed the market over the past year. The fund does not have a hug...

Summary AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintainin...

Summary Healthcare industry, especially the large-cap pharmaceutical, biotechnology, and managed healthcare stocks are doing well and outperforming the market. More stocks in THQ’s top 70 percent equity portfolio generated high positive price growth than the number of stock...

Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Divi...